CYP2C9

From SNPedia
Revision as of 04:20, 22 November 2010 by Jlick (Talk | contribs)

Jump to: navigation, search

is agene
is mentioned by
Full namecytochrome P450, family 2, subfamily C, polypeptide 9
EntrezGene1559
PheGenI1559
VariationViewer1559
ClinVarCYP2C9
dbSNP1559
SADR1559
HugeNav1559
CYPANCcyp2c9
wikipediaCYP2C9
googleCYP2C9
gopubmedCYP2C9
EVSCYP2C9
HEFalMpCYP2C9
23andMeCYP2C9
UniProtP11712
EnsemblENSG00000138109
OMIM601130
EVSCYP2C9
# SNPs31
 Max MagnitudeChromosome positionSummary
Rs1050968096,734,339
Rs105790996,741,051
Rs105791094,981,296Warfarin (Coumadin®)
Rs105791196,748,737
Rs1257235196,703,220
Rs1784704294,981,296
Rs179985394,942,290Warfarin (Coumadin®)
Rs193496394,974,919
Rs193496796,741,426
Rs193496896,741,817
Rs201731996,748,635
Rs225687196,708,974
Rs2837168596,740,981Warfarin (Coumadin®)
Rs2837168696,741,058Warfarin (Coumadin®)
Rs408611696,707,202
Rs491763996,725,535
Rs491875896,697,252
Rs5616545296,741,054
Rs6780736196,698,494
Rs708958096,705,223
Rs7255818794,941,958
Rs7255818896,701,979
Rs7255818994,942,234Warfarin (Coumadin®)
Rs7255819096,707,539
Rs7255819194,947,919
Rs790019496,702,066
Rs933212796,707,471
Rs933213096,709,037
Rs933213196,709,039Warfarin (Coumadin®)
Rs933214696,722,244
Rs933223996,748,777
CYP2C9 is a member of the IIC subfamily of the cytochrome p450 genes, responsible for metabolizing numerous drugs, such as phenytoin, tamoxifen, warfarin, fluvastin, and many nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen and naproxen. People who carry CYP2C9 variants may process such drugs differently.

SNPs in CYP2C9 include:

  • rs1057910; two variants encode the CYP2C9*1 and CYP2C9*3 alleles
  • rs1799853, versions of which encode CYP2C9*2 alleles


A recent FDA action stipulates that the possibility of genetic testing for SNPs in the CYP2C9 gene be included on the label for the medicine known as warfarin (trade name Coumadin).

Plavix, the trade name for clopidogrel, is a drug commonly prescribed to reduce the chance of a type of heart disease (acute coronary syndrome), and it inhibits CYP2C9 at high enough doses. This may therefore interfere with the metabolism of drugs processed by CYP2C9, and individuals with CYP2C9 SNP variants that encode lower metabolizers to begin with would presumably be at greater risk for such side-effects when taking Plavix at the same time as drugs metabolized by CYP2C9.

A more detailed list of CYP2C9 SNPs includes:

Allele Name Defining Name/Change Rs# Comments Enzyme Activity Platforms
CYP2C9*1 Wild-type normal
CYP2C9*2 430C>T rs1799853 R144C inactive 23andMe v1, 23andMe v2, 23andMe v3, HumanOmni1Quad, 23andMe v4
CYP2C9*3 1075A>C rs1057910 I359L inactive 23andMe v1, 23andMe v2, 23andMe v3, Illumina Human 1M, 23andMe v4
CYP2C9*4 1076T>C rs56165452 I359T decreased
CYP2C9*5 1080C>G rs28371686 D360E decreased 23andMe v1, 23andMe v2, 23andMe v3, HumanOmni1Quad, 23andMe v4
CYP2C9*6 818delA rs9332131 273frameshift inactive 23andMe v1, 23andMe v2, 23andMe v3, FTDNA2, FamilyTreeDNA, HumanOmni1Quad, Illumina Human 1M, 23andMe v4
CYP2C9*7 55C>A rs67807361 L19I
CYP2C9*8 449G>A rs7900194 R150H decreased 23andMe v2, 23andMe v3, 23andMe v4
CYP2C9*9 752A>G rs2256871 H251R 23andMe v1, 23andMe v2, 23andMe v3, FTDNA2, FamilyTreeDNA, HumanOmni1Quad, 23andMe v4
CYP2C9*10 815A>G rs9332130 E272G 23andMe v1, 23andMe v2, 23andMe v3, FTDNA2, HumanOmni1Quad, Illumina Human 1M, 23andMe v4
CYP2C9*11 1003C>T rs28371685 R335W decreased 23andMe v1, 23andMe v2, 23andMe v3, FTDNA2, HumanOmni1Quad, Illumina Human 1M, 23andMe v4
CYP2C9*12 1465C>T rs9332239 P489S 23andMe v1, 23andMe v2, 23andMe v3, HumanOmni1Quad, 23andMe v4
CYP2C9*13 269T>C rs72558187 L90P decreased 23andMe v3, HumanOmni1Quad
CYP2C9*14 374G>A rs72558189 R125H
CYP2C9*15 485C>A rs72558190 S162X inactive 23andMe v3, 23andMe v4
CYP2C9*25 353_362delAGAAATGGAA rs72558188 118frameshift inactive 23andMe v3
CYP2C9_42612A>G 42612A>G rs1057909 Y358C 23andMe v1, 23andMe v2, 23andMe v3, FTDNA2, HumanOmni1Quad, Illumina Human 1M, 23andMe v4
CYP2C9_50196C>T 50196C>T rs2017319 A441A 23andMe v1, 23andMe v2, 23andMe v3, FTDNA2, HumanOmni1Quad, Illumina Human 1M, 23andMe v4
CYP2C9_50298A>T 50298A>T rs1057911 G475G 23andMe v3, HumanOmni1Quad

In one of the largest "negative" studies reported to date, three independent studies totaling over 52,000 individuals found no association between CYP2C9 polymorphisms (specifically, the *2 and *3 alleles) and risk of subclinical atherosclerosis, ischemic vascular disease or death after ischemic heart disease.[PMID 19652664]